Response to adjuvant bevacizumab among patients with resected melanoma may vary by age

(American Association for Cancer Research) Younger patients with resected melanoma had some benefit from adjuvant treatment with the anti-VEGF therapeutic bevacizumab (Avastin) while older patients with resected melanoma did not.